Amyloidosis. A clinical overview.

Rheumatic Disease Clinics of North America

Volumn 39, Issue 2, 2013, Pages 323-345

  Hazenberg, Bouke P C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Amyloid fibril; Diagnosis; Disease monitoring; Precursor protein; Protein misfolding; Systemic amyloidosis; Treatment; Typing

Indexed keywords

AMYLOID; AMYLOID A PROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; DOXYCYCLINE; EPRODISATE; GELSOLIN; LYSOZYME; MELPHALAN; PREALBUMIN; PROADRENOMEDULLIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TAUROURSODEOXYCHOLIC ACID; TOCILIZUMAB;

AGE DISTRIBUTION; AGING; AMYLOID LIGHT CHAIN AMYLOIDOSIS; AMYLOIDOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG MECHANISM; DRUG MEGADOSE; ECHOGRAPHY; HUMAN; INCIDENCE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATIENT MONITORING; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN FOLDING; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; SEX RATIO; TISSUE DISTRIBUTION; TREATMENT PLANNING;

AMYLOIDOSIS; DISEASE MANAGEMENT; HUMANS; PROTEIN FOLDING; SERUM AMYLOID A PROTEIN;

EID: 84876722885     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2013.02.012     Document Type: Review

References (95)

1. Kyle R.A. Amyloidosis: a convoluted story. Br J Haematol 2001, 114:529-538.
2. Sipe J.D., Benson M.D., Buxbaum J.N., et al. Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2012, 19:167-170.
3. Merlini G., Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003, 349:583-596.
4. Falk R.H., Comenzo R.L., Skinner M. The systemic amyloidoses. N Engl J Med 1997, 337:898-909.
5. Westermark P. Localized AL amyloidosis: a suicidal neoplasm?. Ups J Med Sci 2012, 117:244-250.
6. Meijer J.M., Schönland S.O., Palladini G., et al. Sjögren's syndrome and localized nodular cutaneous amyloidosis: coincidence or a distinct clinical entity?. Arthritis Rheum 2008, 58:1992-1999.
7. Kyle R.A., Gertz M.A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995, 32:45-59.
8. Lachmann H.J., Goodman H.J., Gilbertson J.A., et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007, 356:2361-2371.
9. Hazenberg B.P., van Rijswijk M.H. Clinical and therapeutic aspects of AA amyloidosis. Baillieres Clin Rheumatol 1994, 8:661-690.
10. Connors L.H., Lim A., Prokaeva T., et al. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003, 10:160-184.
11. Dungu J.N., Anderson L.J., Whelan C.J., et al. Cardiac transthyretin amyloidosis. Heart 2012, 98:1546-1554.
12. Drüeke T.B., Massy Z.A. Beta2-microglobulin. Semin Dial 2009, 22:378-380.
13. Heegaard N.H. Beta(2)-microglobulin: from physiology to amyloidosis. Amyloid 2009, 16:151-173.
14. Valleix S., Gillmore J.D., Bridoux F., et al. Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. N Engl J Med 2012, 366:2276-2283.
15. Benson M.D. Ostertag revisited: the inherited systemic amyloidoses without neuropathy. Amyloid 2005, 12:75-87.
16. Lachmann H.J., Booth D.R., Booth S.E., et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002, 346:1786-1791.
17. Gillmore J.D., Lachmann H.J., Rowczenio D., et al. Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol 2009, 20:444-451.
18. Sattianayagam P.T., Gibbs S.D., Rowczenio D., et al. Hereditary lysozyme amyloidosis - phenotypic heterogeneity and the role of solid organ transplantation. J Intern Med 2012, 272:36-44.
19. Larsen C.P., Walker P.D., Weiss D.T., et al. Prevalence and morphology of leukocyte chemotactic factor 2-associated amyloid in renal biopsies. Kidney Int 2010, 77:816-819.
20. Kiuru S. Gelsolin-related familial amyloidosis, Finnish type (FAF), and its variants found worldwide. Amyloid 1998, 5:55-66.
21. Simms R.W., Prout M.N., Cohen A.S. The epidemiology of AL and AA amyloidosis. Baillieres Clin Rheumatol 1994, 8:627-634.
22. Kyle R.A., Linos A., Beard C.M., et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992, 79:1817-1822.
23. Hemminki K., Li X., Försti A., et al. Incidence and survival in non-hereditary amyloidosis in Sweden. BMC Public Health 2012, 12:974.
24. Janssen S., van Rijswijk M.H., Meijer S., et al. Systemic amyloidosis: a clinical survey of 144 cases. Neth J Med 1986, 29:376-385.
25. Pepys M.B. Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philos Trans R Soc Lond B Biol Sci 2001, 356:203-210.
26. Hazenberg B.P., van Gameren I.I., Bijzet J., et al. Diagnostic and therapeutic approach of systemic amyloidosis. Neth J Med 2004, 62:121-128.
27. Bijzet J., van Gameren I.I., Hazenberg B.P. Fat tissue analysis in the management of patients with systemic amyloidosis. Amyloid and related disorders: surgical pathology and clinical correlations 2012, 191-207. Humana Press, New York. M.M. Picken, A. Dogan, G.A. Herrera (Eds.).
28. Westermark P. Subcutaneous adipose tissue biopsy for amyloid protein studies. Methods Mol Biol 2012, 849:363-371.
29. van Gameren I.I., Hazenberg B.P., Bijzet J., et al. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum 2006, 54:2015-2021.
30. Ikeda S., Sekijima Y., Tojo K., et al. Diagnostic value of abdominal wall fat pad biopsy in senile systemic amyloidosis. Amyloid 2011, 18:211-215.
31. Nilsson K.P., Ikenberg K., åslund A., et al. Structural typing of systemic amyloidoses by luminescent-conjugated polymer spectroscopy. Am J Pathol 2010, 176:563-574.
32. Gertz M.A., Comenzo R., Falk R.H., et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Med 2005, 79:319-328.
33. Kebbel A., Rocken C. Immunohistochemical classification of amyloid in surgical pathology revisited. Am J Surg Pathol 2006, 30:673-683.
34. Satoskar A.A., Efebera Y., Hasan A., et al. Strong transthyretin immunostaining: potential pitfall in cardiac amyloid typing. Am J Surg Pathol 2011, 35:1685-1690.
35. Murphy C.L., Wang S., Williams T., et al. Characterization of systemic amyloid deposits by mass spectrometry. Methods Enzymol 2006, 412:48-62.
36. Lavatelli F., Perlman D.H., Spencer B., et al. Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics 2008, 7:1570-1583.
37. Vrana J.A., Gamez J.D., Madden B.J., et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009, 114:4957-4959.
38. Lavatelli F., Vrana J.A. Proteomic typing of amyloid deposits in systemic amyloidoses. Amyloid 2011, 18:177-182.
39. Brambilla F., Lavatelli F., Di Silvestre D., et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 2012, 119:1844-1847.
40. Picken M.M. Amyloidosis-where are we now and where are we heading?. Arch Pathol Lab Med 2010, 134:545-551.
41. Dispenzieri A., Gertz M.A., Kyle R.A., et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004, 22:3751-3757.
42. Palladini G., Barassi A., Perlini S., et al. Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. Amyloid 2011, 18:216-221.
43. Ozdemir D., Dagdelen S., Erbas T., et al. Amyloid goiter and hypopituitarism in a patient with systemic amyloidosis. Amyloid 2011, 18:32-34.
44. Ishihara T., Nagasawa T., Yokota T., et al. Amyloid protein of vessels in leptomeninges, cortices, choroid plexuses, and pituitary glands from patients with systemic amyloidosis. Hum Pathol 1989, 20:891-895.
45. Erdkamp F.L., Gans R.O., Hoorntje S.J. Endocrine organ failure due to systemic AA-amyloidosis. Neth J Med 1991, 38:24-28.
46. Zubkov A.Y., Rabinstein A.A., Dispenzieri A., et al. Primary systemic amyloidosis with ischemic stroke as a presenting complication. Neurology 2007, 69:1136-1141.
47. Kay J., Benson C.B., Lester S., et al. Utility of high-resolution ultrasound for the diagnosis of dialysis-related amyloidosis. Arthritis Rheum 1992, 35:926-932.
48. Dubrey S.W., Hawkins P.N., Falk R.H. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart 2011, 97:75-84.
49. Noordzij W., Glaudemans A.W., van Rheenen R.W., et al. Iodine-123 labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis. Eur J Nucl Med Mol Imaging 2012, 39:1609-1617.
50. Aprile C., Marinone G., Saponaro R., et al. Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. Eur J Nucl Med 1995, 22:1393-1401.
51. Janssen S., Piers D.A., van Rijswijk M.H., et al. Soft-tissue uptake of 99mTc-diphosphonate and 99mTc-pyrophosphate in amyloidosis. Eur J Nucl Med 1990, 16:663-670.
52. Wechalekar K., Ng F.S., Poole-Wilson P.A., et al. Cardiac amyloidosis diagnosed incidentally by bone scintigraphy. J Nucl Cardiol 2007, 14:750-753.
53. Rapezzi C., Quarta C.C., Guidalotti P.L., et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2011, 4:659-670.
54. Kristen A.V., Haufe S., Schonland S.O., et al. Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. Int J Cardiol 2011, 10.1016/j.ijcard.2011.06.123.
55. 123I-labeled serum amyloid P component. N Engl J Med 1990, 323:508-513.
56. Jager P.L., Hazenberg B.P., Franssen E.J., et al. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value. J Nucl Med 1998, 39:699-706.
57. 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med 2006, 119:355.e15-355.e24.
58. Hawkins P.N., Richardson S., MacSweeney J.E., et al. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression. Q J Med 1993, 86:365-374.
59. 123I-labeled serum amyloid P component in systemic amyloidosis. J Nucl Med 2007, 48:865-872.
60. Wall J.S., Kennel S.J., Stuckey A.C., et al. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood 2010, 116:2241-2244.
61. Gillmore J.D., Lovat L.B., Persey M.R., et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001, 358:24-29.
62. Caorsi R., Federici S., Gattorno M. Biologic drugs in autoinflammatory syndromes. Autoimmun Rev 2012, 12:81-86.
63. Hakala M., Immonen K., Korpela M., et al. Good medium-term efficacy of tocilizumab in DMARD and anti-TNF-α therapy resistant reactive amyloidosis. Ann Rheum Dis 2013, 72:464-465.
64. Gertz M.A., Lacy M.Q., Dispenzieri A., et al. Effect of haematological response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica 2007, 92:1415-1418.
65. Skinner M., Sanchorawala V., Seldin D.C., et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004, 140:85-93.
66. Jaccard A., Moreau P., Leblond V., et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007, 357:1083-1093.
67. Gatt M.E., Palladini G. Light chain amyloidosis 2012: a new era. Br J Haematol 2013, 160:582-598.
68. van Gameren I.I., van Rijswijk M.H., Bijzet J., et al. Histological regression of amyloid in AL amyloidosis is exclusively seen in patients with a complete response of serum free light chain. Haematologica 2009, 94:1094-1100.
69. Wilczek H.E., Larsson M., Ericzon B.G., et al. Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid 2011, 18(Suppl 1):193-195.
70. Okamoto S., Zhao Y., Lindqvist P., et al. Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin amyloidosis (ATTR) patients. Amyloid 2011, 18:200-205.
71. Gustafsson S., Ihse E., Henein M.Y., et al. Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis. Transplantation 2012, 93:1017-1023.
72. Yamamoto S., Gejyo F. Historical background and clinical treatment of dialysis-related amyloidosis. Biochim Biophys Acta 2005, 1753:4-10.
73. Ackermann E.J., Guo S., Booten S., et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 2012, 19(Suppl 1):43-44.
74. Barros S.A., Gollob J.A. Safety profile of RNAi nanomedicines. Adv Drug Deliv Rev 2012, 64:1730-1737.
75. Hammarstrom P., Wiseman R.L., Powers E.T., et al. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003, 299:713-717.
76. Coelho T., Maia L.F., Martins da Silva A., et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012, 79:785-792.
77. Berk J.L., Suhr O.B., Sekijima Y., et al. The diflunisal trial: study accrual and drug tolerance. Amyloid 2012, 19(Suppl 1):37-38.
78. Cardoso I., Martins D., Ribeiro T., et al. Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med 2010, 8:74.
79. Obici L., Cortese A., Lozza A., et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 2012, 19(Suppl 1):34-36.
80. Dember L.M., Hawkins P.N., Hazenberg B.P., et al. Eprodisate for the treatment of AA amyloidosis. N Engl J Med 2007, 356:2349-2360.
81. Inoue S., Hultin P.G., Szarek W.A., et al. Effect of poly(vinylsulfonate) on murine AA amyloid: a high-resolution ultrastructural study. Lab Invest 1996, 74:1081-1090.
82. Hunstein W. Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option?. Blood 2007, 110:2216.
83. Mereles D., Buss S.J., Hardt S.E., et al. Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis. Clin Res Cardiol 2010, 99:483-490.
84. Kristen A.V., Lehrke S., Buss S., et al. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol 2012, 101:805-813.
85. Pepys M.B., Herbert J., Hutchingson W.L., et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002, 417:254-259.
86. Gillmore J.D., Tennent G.A., Hutchinson W.L., et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol 2010, 148:760-767.
87. Hrncic R., Wall J., Wolfenbarger D.A., et al. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol 2000, 157:1239-1246.
88. Bodin K., Ellmerich S., Kahan M.C., et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010, 468:93-97.
89. Coles L.S., Young R.D. Supercentenarians and transthyretin amyloidosis: the next frontier of human life extension. Prev Med 2012, 54(Suppl):S9-S11.
90. Walker L.C., LeVine H. Corruption and spread of pathogenic proteins in neurodegenerative diseases. J Biol Chem 2012, 287:33109-33115.
91. Westermark G.T., Westermark P. Prion-like aggregates: infectious agents in human disease. Trends Mol Med 2010, 16:501-507.
92. Solomon A., Richey T., Murphy C.L., et al. Amyloidogenic potential of foie gras. Proc Natl Acad Sci U S A 2007, 104:10998-11001.
93. Willis M.S., Patterson C. Proteotoxicity and cardiac dysfunction - Alzheimer's disease of the heart?. N Engl J Med 2013, 368:455-464.
94. Schnabel J. Protein folding: the dark side of proteins. Nature 2010, 464:828-829.
95. Pras M., Schubert M., Zucker-Franklin D., et al. The characterization of soluble amyloid prepared in water. J Clin Invest 1968, 47:924-933.